Human papillomavirus type 16 and TP53 mutation in oral cancer: matched analysis of the IARC multicenter study

Cancer Res. 2004 Jan 15;64(2):468-71. doi: 10.1158/0008-5472.can-03-3284.

Abstract

TP53 mutations were analyzed in 35 human papillomavirus (HPV) type 16 DNA-positive cancers of the oral cavity and oropharynx and in 35 HPV DNA-negative cancers matched by subsite, country, sex, age, and tobacco and alcohol consumption. Wild-type TP53 was found more frequently in cancer specimens that contained HPV16 DNA than in those that did not. All 14 HPV16 DNA-positive cancers in HPV16 E6 antibody-positive patients contained wild-type TP53, compared with 50% of corresponding HPV DNA-negative cancers (matched odds ratio, infinity; 95% confidence interval, 1.4- infinity ). In contrast, for HPV16 DNA-positive cancers in E6-negative patients, wild-type TP53 frequency was similar to that in corresponding HPV DNA-negative cancers (matched odds ratio, 1.0; 95% confidence interval, 0.2-5.4). TP53 inactivation is a major mechanism of HPV-related carcinogenesis in the oral cavity and oropharynx. The role of HPV in cancers also containing TP53 mutations remains to be clarified.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Base Sequence
  • Case-Control Studies
  • DNA Primers
  • DNA, Viral / genetics
  • DNA, Viral / isolation & purification
  • Female
  • Geography
  • Humans
  • Male
  • Mouth Neoplasms / genetics*
  • Mouth Neoplasms / virology*
  • Oropharyngeal Neoplasms / genetics
  • Papillomaviridae / genetics*
  • Smoking / epidemiology
  • Tumor Suppressor Protein p53 / genetics*

Substances

  • DNA Primers
  • DNA, Viral
  • Tumor Suppressor Protein p53